Physician

Phillip Hyunsuk Chae, M.D.

According to 2025 Medicare claims, Phillip Chae, M.D. (NPI: 1073833075) practices hematology/oncology in the Midland, TX market, with the plurality of this provider's patient population coming from Midland, TX. This provider's primary affiliated billing organization is TEXAS ONCOLOGY PA (NPI: 1811944101; TIN: 752131429) and primary practice location at 79701-5849.

Chae's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 618 traditional Medicare patients, billed 99,330 HCPCS/CPT codes, and received $1,747,845 in Medicare payments. The top billing code was 99213 (Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more). Part D data shows 2,498 prescription claims across 319 beneficiaries totaling $2,705,737 in drug costs, led by Cabometyx (Cabozantinib S-Malate). DME data shows 71 claims. Open Payments data shows 11 records totaling $5,349. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $36,046 to $1,747,845. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $212,546 to $2,705,737. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	326	486	$36,046
2016	303	14,516	$233,949
2017	520	99,856	$1,490,882
2018	404	90,214	$996,128
2019	649	118,032	$1,676,323
2020	693	87,537	$1,855,453
2021	625	70,826	$1,431,747
2022	652	87,372	$1,477,914
2023	632	94,069	$1,628,305
2024	618	99,330	$1,747,845

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	114	324	$212,546
2016	62	190	$139,838
2017	114	465	$256,705
2018	91	667	$236,882
2019	171	1,158	$561,225
2020	185	1,632	$1,932,615
2021	195	1,577	$2,526,995
2022	304	2,245	$2,292,960
2023	310	2,500	$2,365,064
2024	319	2,498	$2,705,737

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	12	$842
2023	26	67	$7,033
2024	N/R	71	$2,871

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	199	505	$61
99212	Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more	323	449	$35
80053	Blood test, comprehensive group of blood chemicals	337	935	$10
36415	Insertion of needle into vein for collection of blood sample	410	1,242	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	397	1,135	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Cabometyx	Cabozantinib S-Malate	19	570	$493,759
Imbruvica	Ibrutinib	26	730	$405,300
Calquence	Acalabrutinib Maleate	24	720	$351,821
Xtandi	Enzalutamide	17	510	$234,235
Imatinib Mesylate	Imatinib Mesylate	51	1,770	$233,027

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	12	$1,442
J8521	Capecitabine, oral, 500 mg	N	N/R	18	$619
E1392	Portable oxygen concentrator, rental	Y	N/R	12	$441
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	18	$286
J8520	Capecitabine, oral, 150 mg	N	N/R	11	$83

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	9	$5,093	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	2	$256	Genentech, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Phillip Hyunsuk Chae, M.D.?

Tedicare shows public-source Medicare data for Phillip Hyunsuk Chae, M.D. (NPI 1073833075), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Phillip Hyunsuk Chae, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Phillip Hyunsuk Chae, M.D.?

Phillip Hyunsuk Chae, M.D. is linked to TEXAS ONCOLOGY PA (billing NPI 1811944101) in the available physician profile data.

Does Phillip Hyunsuk Chae, M.D. have Open Payments data?

Phillip Hyunsuk Chae, M.D. has 11 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.